BioSpace News Archive

A new study, published in The Lancet Global Health, finds the typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to three years in children as young as nine months old in Malawi.

Captura Biopharma, Inc. is developing oral chelators for the treatment of internal transuranic radionuclide contamination and heavy metal poisoning.

Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round.

VYNE Therapeutics Inc. today announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”).

Lexaria Bioscience Corp. is pleased to announce that it has received a positive full written response from the Food and Drug Administration from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension.

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2023, ended June 30, 2022.

Nanalysis Scientific Corp. announces that on Thursday, August 25, 2022, the Company will put out a press release and Chief Executive Officer Sean Krakiwsky and Interim Chief Financial Officer Randall McRae will host a conference call at 5:00 P.M. Eastern Time to discuss the results for the quarter June 30, 2022.

Peel Therapeutics has initiated a first-in-human clinical study of PEEL-224 in patients with advanced solid tumors.

BiondVax Pharmaceuticals Ltd. announced the successful conclusion of negotiations and formal approval by the European Investment Bank of new terms of its outstanding €24 million loan to BiondVax.

The Lupus Research Alliance (LRA) is pleased to announce the appointment of Albert Roy to President and Chief Executive Officer effective September 6, 2022.